Anti-apoptotic function of L-(-)deprenyl (selegiline) and related compounds

Neurobiology

Volumn 8, Issue 1, 2000, Pages 69-80

  Naoi, M ^a   Maruyama, W ^a   Yagi, K ^a   Youdim, M ^a  

^a Institute of Applied Biochemistry   (Japan)

Author keywords

( )deprenyl; Anti apoptotic function; Neurotoxin; Nitric oxide; Parkinson's disease; Peroxynitrite

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; CATALASE; DNA; DOPAMINE; GLUTATHIONE; LINSIDOMINE; N (4 ETHYL 2 HYDROXYIMINO 5 NITRO 3 HEXEN 1 YL) 3 PYRIDINE CARBOXAMINE; N METHYLSALSOLINOL; NEUROTOXIN; NITRIC OXIDE; NITRIC OXIDE DONOR; PEROXYNITRITE; REACTIVE OXYGEN METABOLITE; SELEGILINE; SEMICARBAZIDE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; NEUROPROTECTION; PARKINSON DISEASE; STRUCTURE ACTIVITY RELATION;

ANTIOXIDANTS; ANTIPARKINSON AGENTS; APOPTOSIS; DNA DAMAGE; DNA FRAGMENTATION; HUMANS; NEUROTOXINS; PARKINSON DISEASE; SALSOLINE ALKALOIDS; SELEGILINE; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROISOQUINOLINES; TUMOR CELLS, CULTURED;

EID: 0033812934     PISSN: 12168068     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease
2. ALS, SOD and peroxynitrite
3. Effect of ethylene mustard aziridinium (AF64A) and of monoamine oxidase-B-inhibitor L-deprenyl on the morphology of the rat hippocampus
4. (-)Deprenyl increases activities of superoxide dismutase and catalase in striatum but not in hippocampus: The sex and age-related differences in the optimal dose in the rat
5. Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites
6. Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats
7. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor
8. Protection against DSP-4 induced neurotoxicity by deprenyl is not related to its inhibition of MAO B
9. Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites
10. Synergetic cytotoxicity of bleomycin and polyhydric alcohols: DNA strand breakage evaluated by 'comet assay'
11. The pharmacology of (-)deprenyl
12. N-Methyl(R)salsolinol produces hydroxyl radicals: Involvement to neurotoxicity
13. Dopamine-derived 1-methyl-6,7-dihydroxyisoquinolines as hydroxyl radical promoters and scavengers in the rat brain: In vivo and in vitro studies
14. An endogenous dopaminergic neurotoxin, N-methyl(R)-salsolinol, induces DNA damage in human dopaminergic neuroblastoma SH-SY5Y cells
15. A neurotoxin N-methyl(R)salsolinol induces apoptotic cell death in differentiated human dopaminergic neuroblastoma SH-SY5Y cells
16. (-)-Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide
17. Histochemical detection of apoptosis in Parkinson's disease
18. Role of selegiline in combination therapy of Parkinson's disease
19. Deprenyl protects dopamine neurons from neurotoxic effect of 1-methyl-4-phenylpyridinium ion
20. L-Deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro
21. L-(-)-Desmethylselegiline, a metabolite of selegiline, protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro
22. Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion
23. Enzymatic oxidation of the dopaminergic neurotoxin, 1(R).2(N)-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, into 1,2-dimethyl-6,7-dihydroxyisoquinolinium ion
24. N-Methyl-(R)salsolinol as a dopaminergic neurotoxin: From an animal model to an early maker of Parkinson's disease
25. Cytotoxicity of an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol relevance to Parkinson's disease
26. Microelectrophoretic study of radiation-induced DNA damage in individual mammalian cells
27. The effect of deprenyl and levodopa on the progression of Parkinson's disease
28. Effect of deprenyl on the progression of disability in early Parkinson's disease
29. Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ishemic damage
30. Increased CNTF gene expression in process-bearing astrocytes following injury is augmented by R(-)-deprenyl
31. Rescue of dying neurons: A new action for deprenyl in MPTP parkinsonism
32. (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis
33. Modulation of gene expression rather than monoamine oxidase inhibition: (-)-Deprenyl-related compounds in controlling neurodegeneration
34. Alkaloids in mammalian tissues. 2. Synthesis of (+) and (-)-1-substituted-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines
35. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease
36. Mitochondrial membrane potential and nuclear changes in apoptosis cased by serum and nerve growth factor withdrawal; Time course and modification by (-)-deprenyl
37. + in vivo
38. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson's disease
39. Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: Relationship of metabolism to MAO B inhibitory potency
40. The effect of repeated doses of (-)-deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline